دراسة عالمية عن ديل-ديسيران لعلاج DM1
This study, called the Global Study of Del-desiran, is looking at a new treatment for Myotonic Dystrophy Type 1 (DM1), also known as Steinert's disease. Researchers want to find out if the medicine, named del-desiran, is safe and effective in improving this condition. Participants will be randomly assigned to receive either del-desiran or a placebo (a treatment with no active medicine) through an IV drip every eight weeks for about a year. Doctors and patients won't know who is getting which treatment. The study will last around 60 weeks in total. Afterwards, there might be an option to continue receiving the medicine in a long-term study, if approved.
نظرة سريعة
ما هو موضوع هذه الدراسة؟
Myotonic Dystrophy Type 1 (DM1), sometimes called Steinert's disease, is a condition that affects muscles, causing them to weaken and have trouble relaxing after use. This can impact many daily activities. Currently, there isn't a cure, and treatments mainly help manage the symptoms. This study aims to see if a new investigative medicine, called del-desiran, could be a helpful treatment for people living with DM1.
This is a 'Phase 3' study, which means it's one of the final stages of testing a new medicine before it might be considered for wider use. It's designed to be 'randomised', meaning participants are put into groups by chance, and 'double-blind', meaning neither the patient nor the doctor knows if they're receiving the new medicine or a placebo (a dummy treatment). This helps ensure the study results are as fair and accurate as possible.
The main goal of this research is to see if del-desiran is safe for people with DM1 and if it can improve their symptoms or slow the progression of the disease. An independent group of experts will regularly check on the study's progress to make sure everyone is safe.
النقاط الرئيسية
- Tests a new medicine (del-desiran) for Myotonic Dystrophy Type 1 (DM1).
- Compares the medicine to a placebo (dummy treatment).
- Participation involves IV infusions every 8 weeks for about a year.
- Aims to check if del-desiran is safe and effective.
- For adults aged 16-65 who can walk independently.
- You won't know if you're getting the active drug or placebo.
من قد يكون مؤهلاً؟
This study is looking for adults aged 16 to 65 who have an official diagnosis of Myotonic Dystrophy Type 1 (DM1), confirmed by genetic testing. You also need to be able to walk by yourself, even if you use aids like ankle braces, for at least 10 metres.
There are also some reasons why you might not be able to join. For example, if you are pregnant, breastfeeding, or planning to become pregnant during the study. You also can't take part if you have serious uncontrolled diabetes, certain heart conditions, or if you've recently taken other experimental medicines.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- Do I have a confirmed diagnosis of Myotonic Dystrophy Type 1 (DM1)?
- Am I between 16 and 65 years old?
- Can I walk on my own for at least 10 metres, even with walking aids?
- Am I not pregnant, breastfeeding, or planning to become pregnant while in the study?
- Do I have generally stable health conditions?
ماذا يتضمن المشاركة؟
If you join this study, you'll first have a screening period that could last up to six weeks to check if you're suitable. The treatment part of the study will then last about 54 weeks. Overall, your involvement will be for around 60 weeks, which is a bit over a year.
During the treatment period, you'll visit the study site every eight weeks to receive either del-desiran or a placebo through an IV drip. You'll receive a total of seven doses, with the last one at Week 48. There will be a final check-up at Week 54. After this, if you meet the requirements and it's approved, you might have the option to join a long-term study where everyone receives the active medicine.
المخاطر والفوائد المحتملة
المواقع (34)
- جامعة ستانفوردالرمز البريدي المؤكدستانفورد، الولايات المتحدة
- جامعة كولورادوالرمز البريدي المؤكددنفر، الولايات المتحدة
- جامعة فلوريداالرمز البريدي المؤكدغينزفيل، الولايات المتحدة
- مركز أبحاث جامعة جنوب فلوريداالرمز البريدي المؤكدتامبا، الولايات المتحدة
- جامعة إنديانا (IU)الرمز البريدي المؤكدإنديانابوليس، الولايات المتحدة
- مركز جامعة كانساس الطبيالرمز البريدي المؤكدكانساس سيتي، الولايات المتحدة
- معهد كينيدي كريجرالرمز البريدي المؤكدبالتيمور، الولايات المتحدة
- مركز بيث إسرائيل ديكونيس الطبيالرمز البريدي المؤكدبوسطن، الولايات المتحدة
- جامعة مينيسوتاالرمز البريدي المؤكدمينيابوليس، الولايات المتحدة
- مركز جامعة روتشستر الطبيالرمز البريدي المؤكدروتشستر، الولايات المتحدة
- مركز جامعة ديوك الطبيالرمز البريدي المؤكددرهام، الولايات المتحدة
- ويك فورستالرمز البريدي المؤكدوينستون-سالم، الولايات المتحدة
أسئلة شائعة
ما هو الحثل العضلي التوتري النوع 1 (DM1)؟
DM1 is a genetic condition that causes muscles to become weak and have difficulty relaxing. It can affect many parts of the body.
ما هو "العلاج الوهمي"؟
A placebo is a dummy treatment that looks exactly like the real medicine but contains no active ingredients. It's used to compare against the new medicine.
Will I know if I'm getting the drug or placebo?
No, this is a 'double-blind' study, meaning neither you nor your doctors will know if you're receiving del-desiran or the placebo until after the study ends.
How often do I need to visit the clinic?
After screening, you'll need to visit the clinic every eight weeks for IV infusions, for a total of seven doses, and a final check-up.
What happens after the study finishes?
After 54 weeks, if you meet certain criteria and it's allowed, you might have the option to join a separate long-term study where you would receive the active medicine.
كيفية معرفة المزيد
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.